SecBot SecBot
8-K ·Filed Apr 3, 2026

VIVS

VivoSim Labs, INC.
NEUTRAL
Impact 5/10
Horizonweeks Processed6mo ago SEC0001193125-26-142106
8-K material event: Items 1.01
Actionable Insight • Neutral

Monitor whether the company meets the conditions for the second tranche funding, as this could provide additional capital. Watch for increased share count from warrant exercises, which could lead to significant dilution.

DirectionNeutral
Confidencehigh
Horizonweeks
Final — all horizons settled through T+60d
VIVS ▼ -38.01% at T+60d
NEUTRAL call -38.01% · α vs SPY -51.48% · entry $1.71 → $1.06
Entry = T+0 close
Apr 3, 2026
via day close
T+1d
-5.26%
call -5.26% · α -5.33%
$1.62
settled 7mo ago
T+5d
-15.79%
call -15.79% · α -19.92%
$1.44
settled 7mo ago
T+20d
-17.54%
call -17.54% · α -26.53%
$1.41
settled 6mo ago
T+60d
-38.01%
call -38.01% · α -51.48%
$1.06
settled 4mo ago

Price Chart

Loading chart...

Executive Summary

VivoSim Labs raised approximately $2.5 million in the initial tranche of a $4 million best-efforts public offering, issuing common stock, pre-funded warrants, and common warrants. The offering includes a potential second tranche of $1 million contingent on stock price and trading volume conditions. The proceeds will be used for working capital and general corporate purposes.

Key Financial Metrics

Deal Value
$2.5M

Key Facts

  • Raised $2.5 million in initial tranche of a $4 million public offering
  • Offering includes common stock, pre-funded warrants, and common warrants
  • Second tranche of $1 million contingent on stock price ≥ $1.43 and average daily trading volume ≥ $100,000
  • Proceeds to be used for working capital and general corporate purposes
  • Joseph Gunnar & Co., LLC served as exclusive placement agent

Financial Impact

$2.5 million in net proceeds from initial tranche, with potential for additional $1 million

cashdilutionequity

Risk Factors

  • Potential for significant dilution from warrant exercises
  • Second tranche funding is contingent on stock performance metrics that may not be met
  • Placement agent warrants and fees increase overall dilution and costs

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-142106
Document: vivs-ex99_1.htm0001193125-26-142106
Document: 0001193125-26-142106-index-headers.html0001193125-26-142106
Document: 0001193125-26-142106-index.html0001193125-26-142106
Document: 0001193125-26-142106.txt0001193125-26-142106
9 reports for VIVS
Performance horizon
100% Hit rate @ T+20 3 of 3 directional calls Went positive at some point 3 of 4 best @ T+60▲ +69.95%Jul 17, 2026
Filters
Rows
Reports for VIVS — sortable, filterable
TypeNow
Oct 16, 2026
9d ago
8-K
BEARISH ★ 5/10
$0.1575awaiting T+20—$0.1483 (+5.84%)
Oct 6, 2026
19d ago
8-K
NEUTRAL ★ 4/10
$0.1915awaiting T+20—$0.1483 (−22.56%)
Sep 16, 2026
5w ago
Press Release
NEUTRAL ★ 5/10
$0.2621 $0.1742▼ −33.54%▼ −36.71%$0.1483 (−43.42%)
Aug 11, 2026
10w ago
EFFECT
BEARISH ★ 7/10
$0.3526 $0.2750▲ +22.01%▲ +20.95%$0.1483 (+57.94%)
Aug 6, 2026
11w ago
8-K
MIXED ★ 6/10
$0.3299 $0.2790▼ −15.43%▼ −16.03%$0.1483 (−55.05%)
Jul 17, 2026
14w ago
8-K
BEARISH ★ 7/10
$0.5790 $0.3225▲ +44.30%▲ +48.75%$0.1483 (+74.39%)
Apr 3, 2026
29w ago
8-K
NEUTRAL ★ 5/10
$1.71 $1.41▼ −17.54%▼ −26.53%$0.1483 (−91.33%)
Apr 1, 2026
29w ago
Press Release
BEARISH ★ 6/10
$1.62 $1.44▲ +11.11%▲ +20.83%$0.1483 (+90.85%)
Apr 1, 2026
29w ago
EFFECT
NEUTRAL ★ 5/10
$1.62 $1.44▼ −11.11%▼ −20.83%$0.1483 (−90.85%)
Showing 9 of 9

US Market Status

Market Open — Closes in 4h 3m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 3, 2026